Tag: AFib

Detecting Irregular Heartbeats (IHB)/AFib Using A&D’s Latest Blood Pressure Monitors.

A&D have a long history and pedigree in pioneering innovation and the development of blood pressure monitors with leading edge functions. With over 40 years of patient-focused thinking it has made them one of the leading blood pressure manufacturers in the world. Their latest clinically validated digital monitors feature a new 2nd generation IHB/AFib algorithm to detect an irregular rhythm during a measurement. 

It is currently available in the latest 2019 versions of the UA-767S AFib+ and UA-767S-W AFib+ from leading distributor PMS Instruments and will be available in more models soon.

It’s the latest development of an Irregular Heartbeat (IHB) detector and algorithm originally pioneered by A&D in 2014. With this feature as well as the existing World Health Organisation (WHO) blood pressure classification index introduced in 2003, A&D monitors really are at the Heart of Healthcare Technology.  

Why is the detection of Atrial Fibrillation important?

AFib is an irregular heart beat that can lead to strokes and other heart related conditions.

The NHS long term plan (NHSLTP) recently published ambitious targets for Atrial Fibrillation (AFib) and high Blood Pressure detection over the next 10 years.

For Atrial Fibrillation the targets are

That 85% of the expected number of people with AF are detected by 2029

That 90% of people with AF who are known to be at high risk of stroke to be adequately anti-coagulated by 2029.

The A&D UA 767S Afib+ and UA-767S-W Afib+ with %IHB/AFib detection could help with these aims.

The monitors classify the %IHB into 4 different grades showing how often an IHB has been detected during the measurement and illustrated by an icon.

0% no indication

1 – 9% grade 1

10 – 24% grade 2

25 – 100% grade 3

This feature is for monitoring purposes only and we recommend contacting your doctor if the grade is high.  

This new feature has been clinically validated and published in the Journal of Clinical Hypertension J Clin Hypertens. 2017;19:1143–1147 Tomoyuki Kabutoya et al. The paper concludes that the new algorithm had high diagnostic accuracy for detecting AF and a low false-positive rate.

Published Clinical Research Demonstrates The Effectiveness Of Key Products

At PMS Instruments we are always looking to share published clinical research that demonstrates the effectiveness of key products we distribute.

At the European Society of Cardiology Congress in Barcelona recently there were a number of clinical studies, papers, posters and presentations focusing on the Kardia Mobile ECG and its effectiveness in AFib detection.

This is important as the research helps validate the accuracy of AliveCors medical grade algorithm giving users’ confidence in Kardia Mobile ECG technology and potentially saving lives.

In one recent Study Professor Julian Halcox of Swansea University Hospital in Wales presented The REHEARSE-AF Study with simultaneous publication in Circulation and the The Journal of the American Heart Association. This randomized study provided AliveCor Kardia units to 500 patients, who used them to record two ECGs per week for a year and compared the results to 500 patients who received conventional care from their General Practitioner. At the end of the year, the Kardia group had a 4-fold increase in AFib diagnosis compared to the control group, thereby enabling the initiation of potentially life-saving anticoagulant therapy.

A Cleveland clinic study showed Kardia Mobile AFib detection accuracy similar to that of Doctors. Dr Khaldoun Tarakji from the Cleveland Clinic presented the iREAD Study which evaluated the accuracy of the AliveCor automatic AFib algorithm versus expert cardiology over-read of both the Kardia recordings and 12-lead ECGs. Dr Tarakji found that in 52 patients the Kardia algorithm had a 96.6% sensitivity and a 94% specificity compared to a cardiology over-read of the simultaneous 12-lead ECGs for the diagnosis of AFib. Additionally, over 93% of the patients found the Kardia to be easy to use and that it “lessened AFib-diagnosis anxiety.”

Another Study found that the Kardia Mobile was able to detect more patients with AFib that were previously undiagnosed. Dr Bryan Yan of The Chinese University of Hong Kong presented research of over 12,000 patients aged 65 and older. He found that for each 30-second ECG recorded using the Kardia Mobile, his team were able to identify more patients with previously undiagnosed AFib. This demonstrates the empirical value of convenient, inexpensive self-screening using the Kardia Mobile ECG.

Finally at the ECS Dr Ngai Yin Chan of Princess Margaret Hospital in Hong Kong presented the AFinder Study which used community volunteers to perform opportunistic screening for AFib using AliveCor’ s Kardia Mobile in over 10,000 Hong Kong citizens age 50 and older. 244 participants were found to have AFib, with 74 of those previously undiagnosed. This study verifies that by using Kardia Mobile senior citizens who were not medical professionals could perform medical screening of their peers with successful identification of a serious medical condition.

These are examples of just some of the many published research articles from around the world which demonstrate that if the AliveCor Kardia Mobile ECG is trusted by Clinicians you can trust it to!